28

2025

-

04

(Flash) Chairman Lei Shaoqing and General Manager Chen Shaoyan of the company visited the South Korean market.

Author:

From April 20 to 25, 2025, Mr. Lei Shaoqing, Chairman of the Board, and Mr. Chen Shaoyan, General Manager, along with Ms. Zhang Hua, Director of Quality, and Mr. Zou Rui, Minister of Safety and Environmental Protection, visited KUKJEON Pharmaceutical Co., Ltd., a South Korean client, for a five-day inspection of the sales situation of Guangchen products in the South Korean market. Through in-depth exchanges with clients and visits to downstream clients, both sides clarified the key points of their next cooperation, and both expressed their willingness to maintain stable cooperation and further expand market share.

From April 20 to 25, 2025, Mr. Lei Shaoqing, Chairman of the Board, Mr. Chen Shaoyan, General Manager, along with Ms. Zhang Hua, Director of Quality, and Mr. Zou Rui, Minister of Safety and Environmental Protection, visited KUKJEON Pharmaceutical Company, a South Korean client, for a five-day inspection of the sales situation of Guangchen products in the South Korean market. Through in-depth exchanges with the client and visits to downstream clients, both sides clarified the focus of their next cooperation, and both expressed their intention to maintain stable cooperation and further expand market share.

Guangchen Pharmaceutical and KUKJEON Pharmaceutical Company conducted in-depth exchanges.

 

Both sides took a commemorative photo.

 

Related News

Linagliptin-Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

Linagliptin-Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

2026-10-19

Linagliptin/metformin extended-release tablets (I), marketed under the brand name LedaTang®, is a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd. and held as the marketing authorization holder; it is also the first extended-release formulation of its kind approved for marketing in China.

Leda Tang — a pharmaceutical product for the treatment of diabetes, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

Leda Tang — a pharmaceutical product for the treatment of diabetes, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

2026-10-19

LE DA TANG is a pharmaceutical brand dedicated to the treatment of diabetes, with its flagship product being “LE DA TANG® Linagliptin–Metformin Extended-Release Tablets (I).” This combination antidiabetic formulation contains the DPP‑4 inhibitor linagliptin and the biguanide metformin hydrochloride. Manufactured by Hubei Guangchen Pharmaceutical Co., Ltd., it is the first domestically approved extended-release formulation of its kind, indicated for glycemic control in adult patients with type 2 diabetes who are suitable for treatment with both linagliptin and metformin.

Leda Tanglirgeletin Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation under the Leda Tang brand, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

Leda Tanglirgeletin Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation under the Leda Tang brand, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

2026-10-19

Ledar Tang® Linagliptin-Metformin Extended-Release Tablets (I) are the first domestically approved extended-release formulation, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd. This product combines the DPP‑4 inhibitor linagliptin with metformin hydrochloride; it is taken once daily, one tablet per dose, with meals, and is indicated, in conjunction with dietary management and exercise, for glycemic control in adult patients with type 2 diabetes who are suitable candidates for treatment with both linagliptin and metformin.

Hubei Guangchen Pharmaceutical Co., Ltd. Has Been Recognized as a Credible Enterprise Abiding by Contracts for the 15th Yichang Session (2024–2025)

2026-08-03